Not recruiting

Study of OMX-0407 for Patients with Previously Treated Unresectable Solid Tumors

Verified siteInvestigationalNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment called OMX-0407, which is a type of medication known as a salt-inducible kinase inhibitor. The study is aimed at patients who have previously been treated for certain types of cancer that cannot be surgically removed, known as unresectable solid tumors. These include specific cancers such as clear cell renal cell carcinoma, squamous non-small cell lung cancer, urothelial carcinoma, and angiosarcoma. The purpose of the study is to explore how safe and tolerable OMX-0407 is for patients, as well as to understand how the body processes the drug.

The study is divided into two main parts. In the first part, the focus is on finding the right dose of OMX-0407 that patients can take safely. This involves gradually increasing the dose to see how much can be given without causing severe side effects. In the second part, the study looks at how well the drug works in treating the cancers mentioned earlier. This includes measuring how long the treatment can keep the cancer from getting worse and how it affects the patients' quality of life.

Participants in the study will take OMX-0407 in capsule form by mouth. The study will monitor the patients over a period to see how they respond to the treatment and to check for any side effects. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of OMX-0407. The study aims to provide valuable information that could lead to new treatment options for patients with these types of cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, eligibility is confirmed based on specific criteria, including age and previous treatments.
Informed consent is required to participate in the study.
Step 2
Dose escalation phase
The primary goal is to identify the dose-limiting toxicities (DLTs) of OMX-0407.
Secondary goals include determining the maximum tolerated dose (MTD) and the recommended dose for the next phase.
Safety and how the body processes the medication are also evaluated.
Step 3
Medication administration
OMX-0407 is administered orally in capsule form.
The dosage and frequency are adjusted based on the findings from the dose escalation phase.
Step 4
Cohort expansion phase
The primary goal is to assess the response rate of OMX-0407 in specific cancer types.
Secondary goals include measuring the duration of response, progression-free survival, overall survival, and quality of life.
Safety and how the body processes the medication continue to be evaluated.
Step 5
Tumor assessments
Tumor assessments are conducted at the start and every 12 weeks thereafter.
For certain cancer types, images are independently reviewed to determine response.
Step 6
End of study
The study is estimated to conclude by June 28, 2025.
Final assessments and data collection are completed to evaluate the overall outcomes of the trial.

Who can join the trial?

21 criteria

Must be at least 18 years old (16 years for certain conditions) and agree to participate in the study.
Must have a type of cancer called **clear cell renal cell carcinoma** (ccRCC) confirmed by a test. If the cancer has mixed types, at least 70% should be clear cell type.
If there is involvement of blood vessels in the kidneys, the patient should be on stable blood-thinning medication before starting the study treatment. A biopsy, which is a small sample of tissue, should be done before starting the blood-thinning medication.
Must have had previous treatment that included **PD-1 blockade** and **VEGFR inhibition**. These are specific types of cancer treatments.
Must have a type of lung cancer called **squamous non-small cell lung cancer** (sqNSCLC) confirmed by a test. If the cancer has mixed types, it should mostly be squamous type.
Must have had previous treatment that included **PD-1 blockade** and **platinum chemotherapy**. These are specific types of cancer treatments.
If there are known genetic changes in the cancer, like **EGFR mutations** or **ALK rearrangements**, the patient must have received specific treatments for these changes.
Must have a type of cancer called **urothelial carcinoma** (UC) confirmed by a test.
Must have had previous treatment that included **platinum-based chemotherapy**, **PD-1 blockade**, and a treatment targeting **Nectin A4**.
Must have a type of cancer called **angiosarcoma** (AS) confirmed by a test, which is advanced or cannot be removed by surgery.
The cancer should be getting worse.
Must have confirmation of advanced cancer through a test.
Must have had at least one previous treatment for cancer that included a **taxane** or an **anthracycline**, which are types of chemotherapy drugs.
Must agree to have small samples of the tumor taken before and during the study treatment, unless it is not safe for health reasons.
Must provide previous tumor samples or agree to have a new sample taken during the screening process.
Must have completed or be unsuitable for standard treatments for their type of cancer, unless these treatments are not available locally. Must have had at least one previous treatment for the cancer type being studied.
Must have a performance status of 0, 1, or 2 according to the **ECOG** scale, which measures how well a person can perform daily activities. For certain phases of the study, the status should be 0 or 1.
Must be able to swallow pills and not have any issues with absorbing food or medicine in the stomach and intestines.
If of childbearing potential, must agree to use two forms of effective birth control during the study and for a period after the study ends. This applies to both male and female participants.
Any side effects from previous cancer treatments must have improved to a mild level or be stable.
Must have a tumor that can be evaluated using specific criteria called **RECIST 1.1**. For certain phases of the study, the disease must be measurable.

Who cannot join the trial?

10 criteria

Patients who have not been previously treated for their solid tumors cannot participate.
Patients with tumors that can be surgically removed are not eligible.
Individuals under the age of 18 are excluded from the study.
Pregnant or breastfeeding women are not allowed to participate.
Patients with serious uncontrolled medical conditions, such as severe heart disease, are excluded.
Individuals with a history of severe allergic reactions to similar medications are not eligible.
Patients currently participating in another clinical trial are not allowed to join this study.
Individuals with active infections that require treatment are excluded.
Patients with a history of drug or alcohol abuse that could interfere with the study are not eligible.
Individuals with mental health conditions that could affect their ability to follow study instructions are excluded.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Cliniques Universitaires Saint-Luc
Responsive
Woluwe-Saint-Lambert, Belgium
Hospital Universitario Hm Sanchinarro
Responsive
Madrid, Spain
Universitair Ziekenhuis Gent
Responsive
Gent, Belgium

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

OMX-0407 is a new medication being studied for its potential to treat patients with solid tumors that cannot be removed by surgery and have already been treated with other therapies. It works by inhibiting a specific enzyme called salt-inducible kinase, which may help to stop or slow down the growth of cancer cells. The study aims to find the best dose of OMX-0407 that patients can tolerate and to understand how the body processes the medication. Researchers are also looking at how effective OMX-0407 is in shrinking tumors and improving patients' quality of life.

Omx-0407

What is already known about the treatment

OMX-0407 – This medication is administered orally and is currently being studied in clinical trials for its effectiveness in treating previously treated unresectable solid tumors. It is in the early stages of research, with ongoing studies to determine its safety, tolerability, and optimal dosing. The main therapeutic indication for OMX-0407 is for patients with certain types of cancer, including clear cell renal cell carcinoma, squamous non-small cell lung cancer, urothelial carcinoma, and angiosarcoma. At the molecular level, OMX-0407 works by inhibiting salt-inducible kinases, which are involved in cancer cell growth and survival. It is classified pharmacologically as a kinase inhibitor, a type of drug that blocks specific enzymes involved in the signaling pathways that promote cancer cell proliferation.

Investigated diseases

Unresectable Solid Tumors – These are abnormal masses of tissue that cannot be surgically removed due to their location, size, or involvement with vital structures. They can occur in various organs and are characterized by uncontrolled cell growth. As the disease progresses, these tumors may grow larger and potentially spread to other parts of the body. The progression can lead to symptoms depending on the tumor's location, such as pain, obstruction, or organ dysfunction. The growth rate and behavior of these tumors can vary widely, influencing the overall impact on the body.